154 results on '"Blatt, Lawrence M."'
Search Results
2. Mechanism of action of hepatitis B virus S antigen transport-inhibiting oligonucleotide polymer, STOPS, molecules
3. Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH.
4. Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models.
5. Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation.
6. Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study
7. Prophylactic and therapeutic intervention of Punta Toro virus ( Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1
8. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model
9. Development of a hyperglycosylated interferon ALFACON1: Towards monthly dosing for antiviral therapies in diseases such as chronic hepatitis C: 257
10. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study
11. Preclinical Characterization of ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis C: 1882
12. Analysis of ALS-2200, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System: 1887
13. ALS-2200, a novel once-daily nucleotide HCV polymerase inhibitor, demonstrates potent antiviral activity over 7 days in treatment-naïve genotype 1 (GT1) patients: 86
14. Relationship of Smoking and Fibrosis in Patients With Chronic Hepatitis C
15. Do guidelines preclude hepatitis B patients from receiving treatment?#
16. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models
17. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma
18. PL-24 A review of treatment of chronic Hepatitis B and C with interferons: Challenges, triumphs and opportunities
19. 72 Pirfenidone blunts induction of bleomycin induced genes associated with idiopathic pulmonary fibrosis in mice
20. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers
21. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis
22. PIRFENIDONE ATTENUATES TRANSFORMING GROWTH FACTOR-BETA-INDUCED ACTIVATION OF P38-ALPHA AND P38-GAMMA MITOGEN–ACTIVATED PROTEIN KINASES IN HUMAN LUNG FIBROBLASTS: IMPLICATIONS FOR TREATMENT OF FIBROTIC LUNG DISEASES
23. THE COMBINATION OF INTERFERON GAMMA-1B AND PIRFENIDONE INHIBITS TRANSFORMING GROWTH FACTOR–BETA-INDUCED GENE INDUCTION IN CELLULAR MODELS OF LUNG FIBROSIS
24. Treatment of Acute Arenaviral Disease with Consensus Interferon-Alpha: 37
25. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C
26. INTERFERON GAMMA-1B INHIBITS INTERLEUKIN-4, ENDOTHELIN-1, AND TRANSFORMING GROWTH FACTOR-BETA–-INDUCED UP-REGULATION OF TYPE I COLLAGEN IN CELLULAR MODELS OF LUNG FIBROSIS
27. PIRFENIDONE MEDIATES DIFFERENTIAL EFFECTS ON LIPOPOLYSACCHARIDE-INDUCED CYTOKINE EXPRESSION IN HUMAN PERIPHERAL MONONUCLEAR CELLS
28. Treatment of Acute Arenaviral Disease with Consensus Interferon-Alpha: 37
29. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
30. Modeling hamsters for evaluating West Nile virus therapies
31. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C
32. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America
33. Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers
34. Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics
35. Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).
36. Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
37. Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
38. Safety, tolerability, and pharmacokinetics of AL-335 in healthy volunteers and hepatitis C virus-infected subjects.
39. Development of a Hyperglycosylated IFN Alfacon-1 (CIFN): Toward Bimonthly or Monthly Dosing for Antiviral Therapies.
40. 257 : Development of a hyperglycosylated interferon ALFACON1: Towards monthly dosing for antiviral therapies in diseases such as chronic hepatitis C
41. Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C.
42. Pharmacokinetics and Tissue Distribution of a Ribozyme Directed Against Hepatitis C Virus RNA Following Subcutaneous or Intravenous Administration in Mice.
43. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes.
44. PS2-39 Development of a hyperglycosylated IFN alfacon1 (CIFN): Towards once a month dosing for antiviral therapy
45. A Predictive Model for the Development of Hepatocellular Carcinoma, Liver Failure, or Liver Transplantation for Patients Presenting to Clinic With Chronic Hepatitis C.
46. Re-treatment of chronic hepatitis C with consensus interferon.
47. Cytokine and Natural Killing Regulation of Growth of a Hairy Cell Leukemia-Like Cell Line: The Role of Interferon-α and Interleukin-2.
48. The Changes in Quantitative HCV RNA Titers During Interferon Alpha 2B Therapy in Patients With Chronic Hepatitis C Infection.
49. PIRFENIDONE IN COMBINATION WITH INTERFERON GAMMA-1B INHIBITS OSTEOPONTIN-INDUCED ALVEOLAR EPITHELIAL CELL PROLIFERATION AND ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASES
50. DEVELOPMENT OF A HIGH THROUGHPUT COLLAGEN ASSAY USING A CELLULAR MODEL OF IDIOPATHIC PULMONARY FIBROSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.